Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
May 01 2023 - 6:45AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that it will host a conference
call and webcast on Friday, May 5, 2023, at 8:00 a.m.
ET to discuss results for the first quarter 2023 and to
provide a corporate update.
To access the conference call:
- U.S. callers should dial 877-407-0989 and international callers
should dial 201-389-0921 approximately five minutes before the call
begins.
- Participants should ask to be connected to the Editas Medicine
Earnings Conference Call.
The conference call will also be webcast and can be accessed
from the “Investors” section of the Editas Medicine website at
https://www.editasmedicine.com. A replay will be available at the
same site approximately one hour after the completion of the
call.
In addition to the conference call, management will participate
in the following upcoming investor conferences:
- Bank of
America 2023 Health Care ConferenceFormat: Fireside
ChatDate: Tuesday, May 9, 2023Time: 5:00 p.m. PT (8:00
p.m. ET)Location: Las Vegas, NV
- 2023 RBC
Capital Markets Global Healthcare ConferenceFormat:
Fireside ChatDate: Tuesday, May 16, 2023Time: 10:30 a.m.
ETLocation: New York, NY
To access the live webcasts of Editas Medicine’s presentations,
please visit the “Investors” section of the Company’s website
at www.editasmedicine.com. An archived replay will be
available for approximately 30 days following each event.
About Editas MedicineAs a
clinical stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cas12a genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute and Harvard University’s Cas9 patent
estates and Broad Institute’s Cas12a patent estate for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2024 to Jul 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2023 to Jul 2024